

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 4, 2009
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 4, 2009.

2. Welcome

Debbie Tapley, RPh, called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Dr. Marion Burton, DHHS Medical Director, was congratulated on his recent election as president-elect of the American Academy of Pediatrics.

3. Committee Members Present:

Ed Behling, MD
Jony Bolinger, MD
Greg Browning, MD
Jim Lindsay, MD

Sara Lindsey, MD
Thomas Phillips, RPh
Tan Platt, MD
Charles Raine, MD

Debbie Tapley, RPh
Edward Vess, RPh
Harry Wright, MD

DHHS Staff Present:

Emma Forkner, Director
Marion Burton, MD
James Assey, RPh
Felicity Myers, PhD
Deidra Singleton, JD
Nikole Boland, JD

Other Representation:

First Health Services – Bryan Amick, PharmD
First Health Services – Mary Roberts, RPh
Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 5, 2009.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. SC DHHS Presentation

Director Forkner presented information regarding the current budgetary condition of SC DHHS. The impact of the various healthcare reform measures currently being debated at the federal level was discussed. Specific items of discussion were the potential expansion of Medicaid and its effect on South Carolina and the role of e-prescribing as a component of the expansion of health information technology.

C. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

| COMPANY | SPEAKER | DRUG |
|-----------------|------------------------|-------------|
| Pfizer, Inc. | Jeffrey Guy, MD | Celebrex® |
| GlaxoSmithKline | Steven Simmons, PharmD | Lovaza® |
| Abbott | Green Neal, MD | Trilipix® |

D. Drug Classes for Review

Bryan Amick, PharmD, First Health Services Corporation, led the discussion for the following drug classes:

- Receptor Selective NSAIDs
- Skeletal Muscle Relaxants
- Triglyceride Lowering Agents

The following are the recommendations of the P & T Committee:

| RECEPTOR SELECTIVE NSAIDS | |
|---------------------------|-------------------|
| Preferred | Non-Preferred |
| MELOXICAM | CELEBREX MOBIC |

| TRIGLYCERIDE LOWERING AGENTS | |
|------------------------------|---------------|
| Preferred | Non-Preferred |
| GEMFIBROZIL | ANTARA |
| TRICOR | FENOGLIDE |
| TRILIPIX | FIBRICOR |
| LOVAZA* | FENOFIBRATE |
| | LOPID |
| | LIPOFEN |
| | LOFIBRA |
| | TRIGLIDE |

*LOVAZA will pay as preferred following failure with any other preferred lipotropic agent.

| SKELETAL MUSCLE RELAXANTS | |
|-----------------------------|---------------|
| Preferred | Non-Preferred |
| BACLOFEN | AMRIX |
| CARISOPRODOL | DANTRIUM |
| CHLORZOXAZONE | FEXMID |
| CYCLOBENZAPRINE | NORFLEX |
| DANTROLENE SODIUM | PARAFON FORTE |
| METHOCARBAMOL | ROBAXIN |
| ORPHENADRINE | SKELAXIN |
| ORPHENADRINE COMPOUND | SOMA |
| ORPHENADRINE COMPOUND FORTE | ZANAFLEX |
| TIZANIDINE HCL | |

5. Old Business

Presentation of the information requested regarding the use of medications in asthmatic children was tabled until the February meeting.

6. New Business

Several issues regarding the managed care options available to Medicaid beneficiaries were discussed.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS:

- Receptor Selective NSAIDs
- Skeletal Muscle Relaxants
- Triglyceride Lowering Agents

8. Closing Comments

The next meeting will be held on Wednesday, February 3, 2010, at 4:00 PM at the same location.

9. Adjournment

The meeting adjourned at 5:20 PM.